125 related articles for article (PubMed ID: 15871818)
1. [Tumoral markers in liver cirrhosis and hepatocellular carcinoma].
Gómez Rubio M; de Cuenca Morón B; Domínguez M
Gastroenterol Hepatol; 2005 May; 28(5):308. PubMed ID: 15871818
[No Abstract] [Full Text] [Related]
2. Abnormal serum tumour markers values do not imply the presence of extra-hepatic malignancies in patients with chronic liver disease.
Puoti C; Bellis L; Guarisco R
Dig Liver Dis; 2010 May; 42(5):387. PubMed ID: 19181575
[No Abstract] [Full Text] [Related]
3. Biomarkers in the treatment of cancer: opportunities and pitfalls.
Melichar B
Clin Chem Lab Med; 2013 Jul; 51(7):1329-33. PubMed ID: 23729626
[No Abstract] [Full Text] [Related]
4. Non-specific tumoral markers in hepatocellular carcinoma.
Stanciu L; Dumitraşcu D; Radu D; Badea R
Med Interne; 1990; 28(2):139-44. PubMed ID: 1702896
[TBL] [Abstract][Full Text] [Related]
5. Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma?
Wang YY; Zhong JH; Lu Z; Qin HG; Li LQ
Tumour Biol; 2015 Nov; 36(11):8273-4. PubMed ID: 26515333
[No Abstract] [Full Text] [Related]
6. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
[TBL] [Abstract][Full Text] [Related]
8. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy.
Schlageter MH; Larghero J; Cassinat B; Toubert ME; Borschneck C; Rain JD
Clin Chem; 1998 Sep; 44(9):1995-8. PubMed ID: 9732993
[No Abstract] [Full Text] [Related]
9. Stability of tumor markers CA 19.9, CA 125, and CA 15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator.
Banfi G; Parma P; Pontillo M
Clin Chem; 1997 Dec; 43(12):2430-1. PubMed ID: 9439470
[No Abstract] [Full Text] [Related]
10. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
11. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma.
Attallah AM; El-Far M; Abdel Malak CA; Farid K; Omran MM; Yahya RS; Saad EA; Albannan MS; Attallah AA; El Basuni MA; Ali IS; Abed SB; El Naggar MA
Ann Hepatol; 2015; 14(6):869-80. PubMed ID: 26436359
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumour markers in endometrial cancer.
Lo SS; Cheng DK; Ng TY; Wong LC; Ngan HY
Tumour Biol; 1997; 18(4):241-9. PubMed ID: 9218009
[TBL] [Abstract][Full Text] [Related]
13. Interchangeability between control material and patient serum in tumor biomarker assessment.
Dittadi R; Gion M
Int J Biol Markers; 2003; 18(3):230-1. PubMed ID: 14535596
[No Abstract] [Full Text] [Related]
14. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
15. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
Pecking AP; Mechelany-Corone C; Pichon MF
Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker guidelines.
Sklaroff RB
J Clin Oncol; 1997 May; 15(5):2175-6. PubMed ID: 9164236
[No Abstract] [Full Text] [Related]
18. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
van Dalen A
Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
[TBL] [Abstract][Full Text] [Related]
19. [Tumor markers in gynecology].
Alekseeva ML; Fanchenko ND; Novikov EA; Margiani FR
Akush Ginekol (Mosk); 1995; (5):35-7. PubMed ID: 8579206
[No Abstract] [Full Text] [Related]
20. Tumor markers in hemodialysis patients.
Arican A; Ozdemir N; Sezer S; Erten Y; Güz G; Turan M; Inanoglu I; Haberal M
Transplant Proc; 1999 Dec; 31(8):3367-8. PubMed ID: 10616509
[No Abstract] [Full Text] [Related]
[Next] [New Search]
